Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Health Claims Data Analysis.
Oncol Ther
; 11(1): 65-81, 2023 Mar.
Article
in En
| MEDLINE
| ID: mdl-36447041
ABSTRACT
INTRODUCTION:
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin's lymphoma with increasing prevalence. Although the disease burden associated with DLBCL is high, only limited data on healthcare resource utilization (HCRU) and associated costs of German patients with DLBCL is available.METHODS:
Using a large claims database of the German statutory health insurance with 6.7 million enrollees, we identified patients who were newly diagnosed with DLBCL between 2011 and 2018 (index date). Treatment lines were identified based on a predefined set of medication. HCRU and related costs were collected for the entire post index period and per treatment line.RESULTS:
A total of 2495 incident DLBCL patients were eligible for the analysis. The average follow-up time after index was 41.7 months. During follow-up, 1991 patients started a first-line treatment, 868 a second-line treatment, and 354 a third-line treatment. Overall, patients spent on average (SD) 5.24 (6.17) days per month in hospital after index. While on anti-cancer treatment, this number increased to nine (10.9) in first-line, 8.7 (13.7) in second-line, and 9.4 (15.8) in third-line treatments. Overall costs per patient per month (PPPM) increased from 421 (875.70) before to 3695 (4652) after index. While on a treatment line, PPPM costs were 17,170 (10,246) in first-line, 13,362 (12,685) in second-line, and 12,112 (16,173) in third-line treatments. Time-unadjusted absolute costs sum up to 59,868 (43,331), 35,870 (37,387), and 28,832 (40,540) during first-line, second-line, and third-line treatments, respectively. The main cost drivers were hospitalizations (71% of total costs) and drug acquisition costs (18% of total costs).CONCLUSIONS:
The financial burden of DLBCL in Germany is high, mainly due to hospitalization and drug costs. Therefore, there is a high medical need for new cost-effective therapeutic options that can lower the disease burden and remain financially viable to support the growing number of patients with this aggressive disease.
Full text:
1
Collection:
01-internacional
Health context:
1_ASSA2030
Database:
MEDLINE
Type of study:
Health_economic_evaluation
/
Risk_factors_studies
Aspects:
Implementation_research
Language:
En
Journal:
Oncol Ther
Year:
2023
Document type:
Article